Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Oakman, Catherine; Tenori, Leonardo; Claudino, Wederson M.; Cappadona, Silvia; Nepi, Stefano; Battaglia, Alessandro; Bernini, Patrizia; Zafarana, Elena; Saccenti, Edoardo; Fornier, Monica; Morris, Patrick G.; Biganzoli, Laura; Luchinat, Claudio; Bertini, Ivano; Leo, Angelo Di

doi:10.1093/annonc/mdq606

Cited by 88 publications

(61 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three other studies [48,49,50] discriminated early versus metastatic cancer [48,50] and time to progression in clinical trials including BC patients receiving anti-HER2 treatment [49]. All three studies used NMR and serum samples.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics Biomarkers for Breast Cancer

Günther

2015

Pathobiology

View full text Add to dashboard Cite

Metabolomics represents a more recent addition to the range of omics tools, which are increasingly used in clinical applications. By measuring the composition of small molecules in tissues, blood or urine, it provides a sensitive molecular readout often associated with disease and its states, especially in cancer. Changes in metabolism related to cancer are increasingly well understood and are seen as a major hallmark of cancer. This review covers metabolomics used in human breast cancers, with a focus on its application in clinical diagnostics. There are clear indications that metabolomics could be a useful addition to currently established clinical diagnostic tools for breast cancer, including the possibility to detect cancer and to predict treatment responses and survival rates from blood and tissue samples.

show abstract

Section: Resultsmentioning

confidence: 99%

“…All three studies used NMR and serum samples. Oakman et al [48] compared the metabolic profiles for progression in patients with localized versus metastatic disease with a sensitivity of 75% and specificity of 69%. Biomarkers reported for metastatic subjects included high values of Phe, Gluc, Pro, Lys and N-acetyl-Cys, and low values of lipids.…”

Section: Resultsmentioning

confidence: 99%

Metabolomics Biomarkers for Breast Cancer

Günther

2015

Pathobiology

View full text Add to dashboard Cite

show abstract

“…One recent attempt was made so far to detect micrometastatic disease in early breast cancer patients from metabolomic analysis of peripheral blood serum [30]. We report here a 1 H-NMR-based metabolomic study aiming at deciphering metabolic serum changes associated with advanced metastatic breast cancer by comparison to the localized disease.…”

Section: Introductionmentioning

confidence: 99%

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer

et al. 2014

View full text Add to dashboard Cite

“…Metabolomics is a post-genomic research field concerned with the study of metabolic profiles in biologic samples such as isolated cells (4), tissues (5) or body fluids (6)(7)(8)(9)(10). In recent years, metabolomic studies have provided a significant contribution to the detailed understanding of the biochemical network and pathways in oncology (11), highlighting the potential of metabolomic analyses of blood samples for the detection of cancers, including epithelial ovarian (12), leukemia (13), oral (14), breast (15,16), prostate (11), liver (17) as well as colorectal cancer (CRC; refs. [18][19][20][21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic Colorectal Cancer

et al. 2012

View full text Add to dashboard Cite

Earlier detection of patients with metastatic colorectal cancer (mCRC) might improve their treatment and survival outcomes. In this study, we used proton nuclear magnetic resonance ( 1 H-NMR) to profile the serum metabolome in patients with mCRC and determine whether a disease signature may exist that is strong enough to predict overall survival (OS). In 153 patients with mCRC and 139 healthy subjects from three Danish hospitals, we profiled two independent sets of serum samples in a prospective phase II study. In the training set, 1 H-NMR metabolomic profiling could discriminate patients with mCRC from healthy subjects with a cross-validated accuracy of 100%. In the validation set, 96.7% of subjects were correctly classified. Patients from the training set with maximally divergent OS were chosen to construct an OS predictor. After validation, patients predicted to have short OS had significantly reduced survival (HR, 3.4; 95% confidence interval, 2.06-5.50; P ¼ 1.33 Â 10 À6 ).A number of metabolites concurred with the 1

show abstract

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Cited by 88 publications

References 44 publications

Metabolomics Biomarkers for Breast Cancer

Metabolomics Biomarkers for Breast Cancer

A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer

Metabolomic NMR Fingerprinting to Identify and Predict Survival of Patients with Metastatic Colorectal Cancer

Contact Info

Product

Resources

About